Comparative Pharmacology
Head-to-head clinical analysis: OSMOVIST 190 versus PANTOPAQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OSMOVIST 190 versus PANTOPAQUE.
OSMOVIST 190 vs PANTOPAQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast media with high osmolality, providing radiographic contrast by attenuating X-rays, primarily due to iodine content.
Pantopaque is an iodinated oil-based contrast agent that attenuates X-rays, allowing visualization of the subarachnoid space during myelography. It acts as a positive contrast medium by increasing the absorption of X-rays in the cerebrospinal fluid.
Intravenous administration of 0.1-0.3 mL/kg (0.19-0.57 mg iodine/kg) for adults; may repeat as needed. Maximum total dose 1.5 mL/kg.
Adults: 5-15 mL (6-18 g iophendylate) intrathecally for myelography via lumbar puncture. No repeated dosing.
None Documented
None Documented
Terminal elimination half-life approximately 110 minutes. In renal impairment, half-life is prolonged, requiring dose adjustment.
Terminal elimination half-life is approximately 6 hours in patients with normal renal function. In renal impairment, half-life is significantly prolonged (up to 24–48 hours in severe impairment), requiring dose adjustment or avoidance.
Primarily renal (glomerular filtration). Excreted unchanged in urine, with less than 2% biliary/fecal excretion.
Primarily renal (glomerular filtration) with approximately 60-70% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for less than 5% of the administered dose; minor metabolism occurs, but the majority is eliminated unchanged via kidneys.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent